IVI and Netherlands
IVI Member State
On October 28, 1996, Permanent Representative of the Kingdom of the Netherlands. H.E. Nicolaas H. Biegman, signed the IVI Establishment Agreement.
On March 2, 1998, the States General of the Netherlands ratified the IVI Establishment Agreement.
Record of Dutch ratification (in Dutch)
In 1998, the Embassy of the Netherlands in Seoul, Korea donated $5,145 USD to IVI.
Dutch Leadership at IVI
Dr. Claire Boog represented the Netherlands on the IVI Board of Trustees from 2010 to 2013.
Professor Bernard Van der Zeijst represented the Netherlands on the IVI Board of Trustees from 2004 to 2010.
Vaccines Against Schistosomiasis for Africa (VASA)
European Union Horizon 2020 Grant: 815643
With a €6.6 million Euro grant from EU Horizons 2020, The University of Cambridge and IVI launched VASA in 2019 to conduct a Phase I clinical study of the SchistoShield® anti-schistosomiasis vaccine in Madagascar. This project includes disease surveillance and cost-effectiveness studies, the formation of a global consortium to advance schistosomiasis vaccine research, and an Integrated Product Development Plan (IPDP) for development of the vaccine backed by the Bill and Melinda Gates Foundation.
The Leiden University Medical Center in the Netherlands is a VASA consortium partner.
In 2013, IVI and Intravacc signed a MoU outlining collaborative opportunities in vaccine technology R&D and vaccinology capacity building in developing countries.